3D Micromac Photo 1 captis executive search management consulting leadership board services

3D-Micromac Eliminates Critical Process Bottlenecks to microLED Display Manufacturing with New Laser Micromachining Platform

3D Micromac Photo 1 captis executive search management consulting leadership board services

The microCETI platform is available in three different configurations, enabling cost-effective transfer, lift-off and repair of microLED devices. Its high speed enables the transfer of hundreds of millions of microLEDs per hour without having to apply mechanical forces – up to several orders of magnitude faster than other approaches – while the on-the-fly square-beam laser enables transfer of nearly any shape and size of microLED. 3D-Micromac has already received multiple system orders for the microCETI platform from leading microLED chip manufacturers in North America and Asia for laser lift-off and transfer processing.

A Promising Display Technology Enabled By Laser Micromachining
MicroLEDs have the potential to revolutionize the display industry, promising a variety of advantages such as superior viewing angle, high dynamic range with perfect black luminance and high brightness, wide color gamut, fast refresh rates, long lifetime and low power consumption. However, the microLED fabrication process is vastly more complex than LCD and OLED manufacturing, and faces several technical challenges that must be overcome before microLEDs can be readily available in the mass market.

Among these challenges is detaching and transferring the processed microLED chips from the donor or growth (e.g., sapphire) substrate to an intermediate substrate for subsequent testing, allowing the expensive growth substrate to be repurposed for future use. Another challenge is to quickly and precisely transfer the chips to the final glass backplane, which for a typical 4K display involving tens of millions of microLED chips could take hundreds of hours using traditional pick-and-place transfer methods. Technologies are also needed that can detect and repair/replace defective microLEDs during the manufacturing process, since a pixel yield rate of 99.9999 percent is required to produce a full-HD desktop display. The microCETI platform from 3D-Micromac supports all laser processes in microLED display manufacturing, with the ability to address precisely these challenges.

According to Uwe Wagner, CEO of 3D-Micromac, “MicroLEDs have enormous potential for future displays across a wide range of applications and end devices, including indoor and outdoor signage, smart watches, augmented and virtual reality headsets, and automotive heads-up displays. As a leader in laser micromachining, 3D-Micromac has extensive experience applying innovative laser technology to new and emerging applications to support their volume-production requirements. Our new microCETI platform provides a high-throughput, versatile and cost-effective laser micromachining process that is ideally suited for the production of microLEDs. We look forward to working with microLED device and display manufacturers to accelerate the adoption of this exciting and promising display technology.”

The microCETI platform is available in one of three configurations:

  • LIFT: unique laser transfer process for nearly every microLED material and shape
  • LLO: on-the-fly laser lift-off suitable for customer related microLED material
  • REPAIR: Single-die-repair process at every step of the microLED production route

The microCETI platform features a high-precision UV-wavelength laser with high repetition rate and an advanced positioning system for three stages (donor stage, substrate stage and mask stage) and up to 16 axes to transfer every microLED with sub-two-micron positioning accuracy and nanometer-scale repeatability. microCETI supports donor wafer sizes ranging from 50mm (2 inches) up to 200mm (8 inches) as well as intermediate/transfer wafers and backplane substrates up to 350mm x 350mm. In addition to microLEDs, the microCETI platform is also suitable for standard LED and miniLED processing.

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

Bioretec appoints a Scientific Advisory Board with Leading International Pros in Traumatology and Orthopedics

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

Bioretec Ltd, a Finnish biotechnology company developing bioabsorbable and bioresorbable implants for traumatology and orthopedic surgery, announced the establishment of a Scientific Advisory Board (SAB).

The SAB includes Prof. Dr. Klaus Dresing, Prof. Dr. Peter Giannoudis, Prof. Dr. Fan Liu, Prof. Dr. Rodrigo Pesantez, and Prof. Dr. Endre Varga. This professionally and academically distinguished group enables an efficient and comprehensive clinical development and evidence of our groundbreaking pipeline products to correspond to global customer needs with their decades of clinical experience from the field.

These honored experts will assist in opening up direct communication into surgeon communities allowing interactive knowledge transfer and sharing clinical experience.

”It is an honor to announce this SAB and integrate these merited leaders of the orthopedic industry with our new RemeOs™ Screw products and material technology development. We are thrilled to have decades of the expertise and impactful accomplishments of SAB members behind us. Their combined resume includes significant professional and academic contributions and influential positions in the global orthopedic community. We are looking forward to this cooperation with our SAB and interesting future activities,” said Timo Lehtonen, CEO of Bioretec.

Members of the Bioretec Scientific Advisory Board include:

Prof. Dr. Klaus Dresing has over 30 years of experience in trauma surgery and orthopedics. He has been the Chairman of the AO Alumni Association and a member of the AO Trauma International Board with various other positions in AO, AO Trauma, and AO Faculty Education Program. In addition, he is the Head and speaker of the German Society for Orthopedics and Trauma Surgery (DGOU) Guidelines Commission and a reviewer in multiple respected orthopedic journals.

Prof. Dr. Peter Giannoudis is a Professor and Chairman of Trauma & Orthopedics, School of Medicine in the University of Leeds. He is an Executive Board Member of EFORT Trauma Task Force, President of ESTROT, and Chair of AO Foundation´s Davos Courses. He has been the President of the British Trauma Society and Chair of the International Committee of Orthopedic Trauma Association (OTA). He has received 20 visiting professorship invitations, almost 700 publications in peer-reviewed journals, and 12 books.

Prof. Dr. Fan Liu has 40 years of experience from surgical trauma and is working currently as Vice President and as Chief and Professor in the Department of Orthopedic Surgery at the Affiliated Hospital to Nantong University. Prof. Dr. Liu is the Vice President of the Chinese Orthopedic Association and the Chinese Association of Orthopedic Surgeons. He is an editor in a number of orthopedic journals and a globally awarded scientific researcher.

Prof. Dr. Endre Varga is the Professor and Head of Trauma Department in Szeged, Hungary. He is the founder of ATLS European Committee and Past President of the Hungarian Trauma Society, Senior AO Trustee, and Honorary President of the AO Trauma Hungarian Chapter. He has done research in bioabsorbable materials with 92 scientific publications/book chapters. Prof. Dr. Varga is also a corresponding (honorary) member of DGU (Deutsche Gesellschaft fûr Unfallchirurgie).

Prof. Dr. Rodrigo Pesantez is the current Chairperson of AO Trauma Latin America (AOTLA). President of the Trauma in the Colombian Orthopedic Society and trustee of the AO Foundation, and director in multiple AO Trauma courses worldwide. He is an orthopedic trauma surgeon specialized in hip, trauma, and reconstruction. He has published multiple articles in peer-reviewed journals and written and edited orthopedic books.

NPJDig Med Image1 captis executive search management consulting leadership board services

Artificial Intelligence Tool Uses Chest X-ray to Differentiate Worst Cases of COVID-19

NPJDig Med Image1 captis executive search management consulting leadership board services

Trained to see patterns by analyzing thousands of chest X-rays, a computer program predicted with up to 80 percent accuracy which COVID-19 patients would develop life-threatening complications within four days, a new study finds.

Developed by researchers at NYU Grossman School of Medicine, the program used several hundred gigabytes of data gleaned from 5,224 chest X-rays taken from 2,943 seriously ill patients infected with SARS-CoV-2, the virus behind the infections.

The authors of the study, publishing in the journal npj Digital Medicine online May 12, cited the “pressing need” for the ability to quickly predict which COVID-19 patients are likely to have lethal complications so that treatment resources can best be matched to those at increased risk. For reasons not yet fully understood, the health of some COVID-19 patients suddenly worsens, requiring intensive care, and increasing their chances of dying.

In a bid to address this need, the NYU Langone team fed not only X-ray information into their computer analysis, but also patients’ age, race, and gender, along with several vital signs and laboratory test results, including weight, body temperature, and blood immune cell levels. Also factored into their mathematical models, which can learn from examples, were the need for a mechanical ventilator and whether each patient went on to survive (2,405) or die (538) from their infections.

Researchers then tested the predictive value of the software tool on 770 chest X-rays from 718 other patients admitted for COVID-19 through the emergency room at NYU Langone hospitals from March 3 to June 28, 2020. The computer program accurately predicted four out of five infected patients who required intensive care and mechanical ventilation and/or died within four days of admission.

“Emergency room physicians and radiologists need effective tools like our program to quickly identify those COVID-19 patients whose condition is most likely to deteriorate quickly so that health care providers can monitor them more closely and intervene earlier,” says study co-lead investigator Farah Shamout, PhD, an assistant professor in computer engineering at New York University’s campus in Abu Dhabi.

“We believe that our COVID-19 classification test represents the largest application of artificial intelligence in radiology to address some of the most urgent needs of patients and caregivers during the pandemic,” says Yiqiu “Artie” Shen, MS, a doctoral student at the NYU Data Science Center.

Study senior investigator Krzysztof Geras, PhD, an assistant professor in the Department of Radiology at NYU Langone, says a major advantage to machine-intelligence programs such as theirs is that its accuracy can be tracked, updated and improved with more data. He says the team plans to add more patient information as it becomes available. He also says the team is evaluating what additional clinical test results could be used to improve their test model.

Geras says he hopes, as part of further research, to soon deploy the NYU COVID-19 classification test to emergency physicians and radiologists. In the interim, he is working with physicians to draft clinical guidelines for its use.

Funding support for the study was provided by National Institutes of Health grants P41 EB017183 and R01 LM013316; and National Science Foundation grants HDR-1922658 and HDR-1940097.

Besides Geras, Shamout, and Shen, other NYU Langone researchers involved in this study are co-lead investigators Nan Wu; Aakash Kaku; Jungkyu Park; and Taro Makino; and co-investigators Stanislaw Jastrzebski; Duo Wong; Ben Zhang; Siddhant Dogra; Men Cao; Narges Razavian; David Kudlowitz; Lea Azour; William Moore; Yvonne Lui; Yindalon Aphinyanaphongs; and Carlos Fernandez-Granda.

BF UC190F EBUS Bronchoscope 1 captis executive search management consulting leadership board services

Olympus Announces New Endobronchial Ultrasound Bronchoscope (EBUS)

BF UC190F EBUS Bronchoscope 1 captis executive search management consulting leadership board services

Olympus announced today the market launch of the FDA 510(k)-cleared BF-UC190F endobronchial ultrasound (EBUS) bronchoscope, the newest addition to its robust EBUS portfolio of devices for minimally invasive lung cancer diagnosis and staging via needle biopsy.

Today, more than 1,600 clinical cases using the Olympus EBUS solution prove that EBUS-TBNA (transbronchial needle aspiration) is an effective biopsy solution, providing higher diagnostic yield with greater sensitivity and specificity in lymph nodes ≥5 mm. According to the American College of Chest Physicians (ACCP), correctly staging lung cancer is critical, because the treatment options and prognosis differ significantly by stage, and the ACCP recommends EBUS-TBNA as the optimal first test rather than surgery for mediastinal staging.

In conjunction with the versatile Olympus ViziShot EBUS-TBNA needle portfolio, the BF-UC190F allows physicians to access and sample difficult-to-reach targets such as lymph nodes in the mediastinum (4L) and hilum (10R). Key design features of the BF-UC190F that enable improved access and sampling include:

  • Powerful Scope Angulation: With an increase in angulation from 120 degrees to 160 degrees, this new EBUS-TBNA bronchoscope has the flexibility to ensure the correct positioning of the scope tip relative to the target.
  • Compact Distal Tip: With a distal diameter of 6.6mm, the BF-UC190F is smoother to insert and easier to maneuver within the lung.
  • Steeper Puncture Angle: A more perpendicular needle orientation allows for smoother penetration between cartilage rings and other critical anatomy.
  • Enhanced Endoscopic View: With a decreased forward oblique angle of 20 degrees and higher resolution images, the BF-UC190F increases the field of view and improves visualization of the anatomy for more precise airway navigation and abnormality detection.

“When reaching a lymph node to obtain a tissue sample, it is critical to be able to achieve the correct positioning within the lung. In my study of this new EBUS-TBNA bronchoscope, I found that the sharper puncture angle greatly improves the ability of physicians to puncture the lymph node precisely without needing to use more force or to alter technique,” said Kazuhiro Yasufuku, MD, Ph.D., FRCSC, Professor, and Chair of Thoracic Surgery at the University of Toronto and the William Coco Chair in Surgical Innovation for Lung Cancer at the University Health Network. “The BF-UC190F bronchoscope is a valuable advancement in the use of EBUS-TBNA for the diagnosis and staging of lung cancer.”

“We are very excited to launch this next-generation EBUS bronchoscope, which will further the ability of physicians to biopsy mediastinal and hilar lymph nodes through a minimally invasive procedure,” said Lynn Ray, Vice President and General Manager of the Global Respiratory Business Unit for Olympus Corporation. “Our goal as a company is to develop leading-edge technology that helps physicians diagnose disease earlier and more accurately, which can save lives.”

According to the American Cancer Society, lung cancer is the second most common cancer and the leading cause of cancer death in the US — in 2021, an estimated 235,760 people were diagnosed with lung cancer, and 131,880 people died of the disease.  While lung cancer has an overall five-year survival rate of only 20 percent, lung cancer detected and treated at an early stage increases the chance of survival beyond five years.

In March 2021, the U.S. Preventive Services Task Force (USPSTF) announced new recommendations for annual lung cancer screening using low-dose computed tomography (LDCT) for people at high risk for lung cancer, lowering the screening age to 50 and lowering the smoking threshold to 20 pack-years, or those who currently smoke or have quit within the past 15 years

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

ACUVUE Abiliti Overnight Therapeutic Lenses for Myopia Management Receives FDA Approval

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

ACUVUE Abiliti Overnight Therapeutic Lenses has received U.S. Food and Drug Administration (FDA) approval reports Johnson & Johnson Vision.

This is the first and only FDA-approved orthokeratology (ortho-k) contact lens for the management of myopia.

“The FDA approval of AbilitiOvernight marks an important milestone in our commitment to help change the trajectory of eye health and reshape the future of children with myopia,” said Xiao-Yu Song, MD, PhD, Global Head of Research & Development, Johnson & Johnson Vision. “We look forward to supporting parents and eye care professionals in their care of children with comprehensive resources, starting with AbilitiOvernight Therapeutic Lenses, and continuing with additional products and services to address the progression of myopia.”

Myopia is sometimes called ‘nearsightedness’ but it is much more. It is a chronic and progressive disease that poses the biggest eye health threat of the 21st Century1. Young children that are less than 12 years of age and become myopic are the most vulnerable to develop high myopia and can be at increased risk of sight-threatening eye diseases later in life2. Additionally, half of the world’s population is projected to be myopic by 2050 with nearly one billion people expected to have high myopia.

Clinical studies have demonstrated that ortho-k lenses can be a safe and effective treatment option to manage myopia. AbilitiOvernight ortho-k contact lenses are specifically designed and fitted to match the eye based on its unique corneal shape to temporarily reshape the cornea8. Abiliti Overnight will be available in two different contact lens designs: AbilitiOvernight Therapeutic Lenses, and Abiliti Overnight Therapeutic Lenses for Astigmatism.

Abiliti Overnight contact lenses are optimized by the use of corneal topography, refractive error and other measurements connected to an innovative fitting software. The software is a sophisticated and user-friendly tool that provides a precise measure of the corneal shape, and accurately guides the eye care professional through the fitting process for consistent and successful first fit rates of approximately 90%

“The prevalence of myopia in children is increasing, and as optometrists we are on the front lines of this epidemic that may threaten the vision of future generations,” said Moshe Mendelson, OD, FIAO. “For too long we have relied on increasing the prescription of glasses for children, while having few resources to address the underlying disease and help change this worrying trajectory of eye health. The FDA approval of AbilitiOvernight will provide eye care professionals and parents with more options to manage myopia.”

Johnson & Johnson Vision is collaboratively advancing the next generation of science, research and development with the potential to transform standards of care in myopia. Earlier this year, the company announced the development of a first-of-its-kind myopia management guide with recommendations for eye care professionals to assess, monitor and treat myopia in children. The FDA approval of Abiliti Overnight stems from the collaboration of Johnson & Johnson Vision with Menicon to bring forward therapeutic contact lenses for the treatment of myopia under the ACUVUE® Abiliti Brand – a new brand for future products and services to help parents and eye care professionals address the progression of myopia in children.

Each annual purchase of an Abiliti product will provide a free comprehensive eye health exam to a child in need through Sight for Kids – a joint program from Johnson & Johnson Vision and the not-for-profit program from the Lions Clubs International Foundation (LCIF). Sight for Kids is one of the largest-known, school-based eye health programs that mobilizes LCIF and eye care professionals to provide comprehensive eye health services in low-income schools around the world.

ACUVUE Abiliti Overnight contact lenses are expected to be available in the U.S. by the end of 2021. Parents and eye care professionals who want more information can visit here.

Vyv captis executive search management consulting leadership board services

Vyv Announces Groundbreaking Inactivation And Killing Of Viruses With Its UV-free Antimicrobial Light Technology

Vyv captis executive search management consulting leadership board services

Vyv, a female-founded and led health-tech industry leader and pioneer of antimicrobial LED technology, announces the recent independent test results confirming efficacy of its antimicrobial light technology (405nm) for killing* viruses.

Numerous studies have proven the effectiveness of Vyv’s visible light against bacteria, mold, fungi, and yeast.

This recent study has confirmed, through an independent third-party lab, Vyv’s antimicrobial LED products are also effective against non-enveloped viruses, which are the most difficult class of virus to kill*.

“The implications of this are vast because, unlike harmful UV-C light, Vyv’s patented technology can be used continuously and without restriction 24/7 around people, animals, and plants. The recent findings of enhanced efficacy against viruses greatly expand the antimicrobial impact delivered to spaces currently protected with Vyv technology, as well as in new spaces,” said Vyv CEO and co-founder Colleen Costello. “With our overhead LED products, Vyv is already lighting offices, schools and school buses, athletic centers, factories and hospitals. We’re also embedding the same technology in many challenging spaces, including behind elevator buttons, inside consumer products such as humidifiers and bathroom fans, and in airplanes, trains, and public buses.”

Additionally, a recent separate third-party study completed by the Icahn School of Medicine at Mount Sinai also demonstrated efficacy results using ranges of light in the 400-420nm range on inactivating enveloped viruses. With Vyv’s commitment to ongoing research and development advancements of a myriad of new products for healthier spaces, the company will continue to expand its virus testing in the coming months.

The company has announced several high-profile business partnerships and investments with industry front-runners over the past six months. While the COVID-19 global pandemic continues to impact day-to-day life around the world, Vyv has joined forces and expanded development projects with Middleby Corporation, Citi, NJ Transit, Delta Air Lines, Broan-NuTone, Dorel Juvenile and Brilli, among several other well-respected brands. Most recently, Vyv announced a partnership with the Healthcare Association of New York State (HANYS), which is working to advance new approaches to infection control and prevention by dosing interior environments continuously with antimicrobial light to stop and kill* viruses, bacteria, fungi, mold and other organisms.

“Our partners have long understood the threats to global health and wellness. Many of these companies began engineering new solutions with Vyv’s antimicrobial light long before the current pandemic. We’ve been on a path together to bring a new class of continuous microbial protection to address the world’s ever-evolving microbial challenges,” said Costello.

Paragon 28 captis executive search management consulting leadership board services

Paragon 28 Conducts the First Total Ankle Joint Replacement Surgery Utilizing Laser Alignment Technology

Paragon 28 captis executive search management consulting leadership board services

Medical Device News Magazine uses cookies to constantly improve our internet content and to create internal assessments pursuant to our data protection guidelines. We use cookies to personalize content and ads, to provide social media features, and analyze our traffic. We also share information about your use of our site with our social media, advertising and analytics partners.  To find out more about our cookie policy on this website, see our Privacy Policy.

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

Royal Philips 130 Years of Innovation, Collaboration, and Social Responsibility

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

Philips’ recognition of its social responsibility goes as far back as 1932, when it started screening its staff, and eventually the whole population of Eindhoven (the Dutch city where the company was founded) for tuberculosis. In the 1990s Philips helped to pioneer the Dutch national breast cancer screening program.

Today, the company’s Environmental, Social and Corporate Governance (ESG) commitments are enshrined in its new 5-year ESG targets and strategic plans. Philips is already carbon neutral in its operations and is set to further reduce its CO2 emissions in line with 1.5°C global warming and source 75% of its total energy consumption from renewables. The company also aims to increase revenue from circular economy solutions to 25% of sales by 2025.

As part of its target to improve the lives of 2.5 billion people a year by 2030, Philips is committed to improving access to care for 400 million people in underserved communities. In collaboration with key strategic partners and the Philips Foundation, it is enabling care in resource constrained settings, for example, by putting portable ultrasound solutions into the hands of trained midwives at primary care facilities in Kenya, and establishing hospital-based cardiology centers in regional cities across India.

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

UltraSight Raises $13 million to Bring AI Guidance for Cardiac Ultrasound to Patient Point of Care

Untitled 1 1024x538 1 captis executive search management consulting leadership board services

UltraSight (formerly OnSight Medical), a Digital Health pioneer for cardiac imaging and beyond, announced today that it has closed a $13 million Series B funding round.

The investment will be used to advance U.S. clinical programs for its real time, AI guidance in a variety of care settings. The Yozma Group Korea, Atain Specialty Insurance Company and the Weizmann Institute of Science participated in the round.

UltraSight’s AI platform provides the engine for ultrasound devices to conduct sonography at the point of care, helping more patients be accurately diagnosed and treated.  Point of care ultrasound allows medical professionals to diagnose patients wherever they are including clinics, community hospitals, ambulances and remote settings. Currently, cardiac sonography is a skill that takes years to acquire and requires daily practice to maintain high proficiency, creating a shortage in these highly specialized professionals. UltraSight aims to change this dynamic by offering clinicians with no prior sonography training, automated guidance and quality assessment, for conducting ultrasound scans.

UltraSight also announced the strengthening of its medical and scientific advisory board with the appointment of Al Lojewski, former General Manager Cardiology Solutions at GE Healthcare, Laurance Grossman, MD, Radiologist at Cleveland Clinic, and Andrew Cleeland, CEO of Fogarty Innovation.

“We see a future where ultrasound is readily available to assess any patient, anywhere and by any healthcare professional. Simplifying ultrasound is critical to providing fast, effective care,” said Andrew Cleeland, CEO of Fogarty Innovation. “By making ultrasound ubiquitous, UltraSight has the potential to bring the benefits of cardiac imaging to more healthcare professionals and new care settings.”

“UltraSight provides a novel and versatile platform that addresses the unmet needs of patients and physicians,” said Davidi Vortman, CEO of UltraSight. “This financing round places us on the path to become a leading player in the ultrasound industry.”

“We are excited to help realize UltraSight’s mission,” said Wonjae Lee, Head of Asia Pacific, The Yozma Group. “UltraSight’s innovation is poised to reshape the ultrasound market and propel market growth.”

jon hopkins captis executive search management consulting leadership board services

Jon Hopkins New Senior Vice President-Chief Development Officer of Legion Healthcare Partners

jon hopkins captis executive search management consulting leadership board services

Medical Device News Magazine uses cookies to constantly improve our internet content and to create internal assessments pursuant to our data protection guidelines. We use cookies to personalize content and ads, to provide social media features, and analyze our traffic. We also share information about your use of our site with our social media, advertising and analytics partners.  To find out more about our cookie policy on this website, see our Privacy Policy.